{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:57:04Z","timestamp":1791320224558,"version":"4.3.1"},"reference-count":126,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.hfc.2012.04.001","type":"journal-article","created":{"date-parts":[[2012,6,30]],"date-time":"2012-06-30T05:33:57Z","timestamp":1341034437000},"page":"413-425","source":"Crossref","is-referenced-by-count":60,"title":["Pulmonary Arterial Hypertension in Connective Tissue Diseases"],"prefix":"10.1016","volume":"8","author":[{"given":"Stephen C.","family":"Mathai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2012.04.001_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(98)02111-4","article-title":"Primary pulmonary hypertension","volume":"352","author":"Gaine","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2012.04.001_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension. A national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib4","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2012.04.001_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","article-title":"Endothelial dysfunction in pulmonary hypertension","volume":"109","author":"Budhiraja","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2012.04.001_bib6","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0002-9343(92)90238-7","article-title":"Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku","volume":"93","author":"Isern","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1378\/chest.123.2.344","article-title":"Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis","volume":"123","author":"Kawut","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.hfc.2012.04.001_bib10","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.22069","article-title":"Clinical differences between idiopathic and scleroderma-related pulmonary hypertension","volume":"54","author":"Fisher","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-140-2-200401200-00013","article-title":"Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis","volume":"140","author":"Jimenez","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0889-857X(03)00015-2","article-title":"Systemic sclerosis: the susceptible host (genetics and environment)","volume":"29","author":"Tan","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.hfc.2012.04.001_bib14","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0889-857X(03)00022-X","article-title":"Scleroderma epidemiology","volume":"29","author":"Mayes","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.hfc.2012.04.001_bib16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/rheumatology\/27.4.286","article-title":"An epidemiological study of scleroderma in the West Midlands","volume":"27","author":"Silman","year":"1988","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/BF00371817","article-title":"Epidemiological study of patients with systemic sclerosis in Tokyo","volume":"283","author":"Tamaki","year":"1991","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.hfc.2012.04.001_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/rheumatology\/keh124","article-title":"A\u00a0study of\u00a0the\u00a0prevalence of systemic sclerosis in northeast\u00a0England","volume":"43","author":"Allcock","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.hfc.2012.04.001_bib19","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib20","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1002\/art.21433","article-title":"Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study","volume":"52","author":"Hachulla","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.hfc.2012.04.001_bib22","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1378\/chest.110.6.1515","article-title":"Prevalence of pulmonary hypertension in limited and diffuse scleroderma","volume":"110","author":"Battle","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.hfc.2012.04.001_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/art.1780290409","article-title":"Pulmonary hypertension in the CREST syndrome variant of\u00a0systemic sclerosis","volume":"29","author":"Stupi","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib24","first-page":"639","article-title":"Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody","volume":"23","author":"Sacks","year":"1996","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/rheumatology\/40.4.453","article-title":"Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival","volume":"40","author":"MacGregor","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.hfc.2012.04.001_bib26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1164\/rccm.200811-1691OC","article-title":"Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension","volume":"179","author":"Fisher","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib27","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hfc.2012.04.001_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.hfc.2012.04.001_bib30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0889-857X(05)70295-7","article-title":"Systemic sclerosis. A vascular perspective","volume":"22","author":"LeRoy","year":"1996","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.hfc.2012.04.001_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0190-9622(80)80396-3","article-title":"Capillary alterations in scleroderma","volume":"2","author":"Fleischmajer","year":"1980","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib32","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/1529-0131(200011)43:11<2550::AID-ANR24>3.0.CO;2-H","article-title":"Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95","volume":"43","author":"Sgonc","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/sarh.2002.50011","article-title":"Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis","volume":"32","author":"Cerinic","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/art.1780340405","article-title":"Predictors of survival in systemic sclerosis (scleroderma)","volume":"34","author":"Altman","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib35","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/rheumatology\/34.11.1048","article-title":"Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis","volume":"34","author":"Denton","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib36","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar596","article-title":"Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers","volume":"4","author":"Distler","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.hfc.2012.04.001_bib37","first-page":"1529","article-title":"Elevated vascular endothelial growth factor in systemic sclerosis","volume":"30","author":"Choi","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib38","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/1529-0131(200004)43:4<889::AID-ANR21>3.0.CO;2-5","article-title":"Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis","volume":"43","author":"Hebbar","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/art.1780350114","article-title":"Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis","volume":"35","author":"Okano","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib40","first-page":"462","article-title":"Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension","volume":"25","author":"Negi","year":"1998","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib41","first-page":"1688","article-title":"Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis","volume":"22","author":"Fritzler","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib42","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1164\/ajrccm.155.1.9001324","article-title":"Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7","volume":"155","author":"Morse","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib43","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2249.2000.01320.x","article-title":"Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35","volume":"121","author":"Grigolo","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.hfc.2012.04.001_bib44","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1183\/09031936.05.00045705","article-title":"Autoimmunity and pulmonary hypertension: a perspective","volume":"26","author":"Nicolls","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hfc.2012.04.001_bib45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/thx.2004.029082","article-title":"Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension","volume":"60","author":"Tamby","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.hfc.2012.04.001_bib46","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.10361","article-title":"Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis","volume":"46","author":"Chizzolini","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.06.00152705","article-title":"Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension","volume":"28","author":"Tamby","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hfc.2012.04.001_bib48","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1164\/rccm.200707-1015OC","article-title":"Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension","volume":"177","author":"Terrier","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib49","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.hfc.2012.04.001_bib50","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/303059","article-title":"Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene","volume":"67","author":"Deng","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.hfc.2012.04.001_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium","volume":"26","author":"Lane","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.hfc.2012.04.001_bib52","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.1016\/j.jacc.2004.02.028","article-title":"Genetic basis of pulmonary arterial hypertension: current understanding and future directions","volume":"43","author":"Newman","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2012.04.001_bib53","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1136\/jmg.2004.023101","article-title":"Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension","volume":"41","author":"Koehler","year":"2004","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.hfc.2012.04.001_bib54","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3109\/07853890109002105","article-title":"Genetic aspects of pulmonary arterial hypertension","volume":"33","author":"Morse","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJM200108023450503","article-title":"Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia","volume":"345","author":"Trembath","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib56","first-page":"2379","article-title":"Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations","volume":"29","author":"Morse","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib57","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/art.10487","article-title":"Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases","volume":"46","author":"Tew","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.hfc.2012.04.001_bib58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0022-202X.2004.23512.x","article-title":"The -2518 promoter polymorphism in the MCP-1 gene is associated with systemic sclerosis","volume":"124","author":"Karrer","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib59","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.20674","article-title":"Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis","volume":"50","author":"Tsuchiya","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.imlet.2004.08.002","article-title":"-238 and\u00a0+489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with systemic sclerosis","volume":"96","author":"Tolusso","year":"2005","journal-title":"Immunol Lett"},{"key":"10.1016\/j.hfc.2012.04.001_bib61","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/art.10736","article-title":"Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population","volume":"48","author":"Kawaguchi","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib62","first-page":"81","article-title":"Interleukin 1alpha single-nucleotide polymorphism associated with systemic sclerosis","volume":"31","author":"Hutyrova","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib63","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/rheumatology\/keg420","article-title":"Analysis of the 5\u2032 flanking region of the interleukin 10 gene in patients with systemic sclerosis","volume":"42","author":"Crilly","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.hfc.2012.04.001_bib64","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/art.11220","article-title":"Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence","volume":"48","author":"Zhou","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib65","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/rheumatology\/kel378","article-title":"Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension","volume":"46","author":"Wipff","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.hfc.2012.04.001_bib66","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1378\/chest.124.6.2098","article-title":"Age and risk of pulmonary arterial hypertension in scleroderma","volume":"124","author":"Schachna","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.hfc.2012.04.001_bib67","first-page":"269","article-title":"Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma","volume":"33","author":"Chang","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib68","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib69","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.23187","article-title":"High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis","volume":"58","author":"Allanore","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.hfc.2012.04.001_bib70","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3899\/jrheum.090697","article-title":"Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension","volume":"37","author":"Shah","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib71","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.echo.2005.12.003","article-title":"Right heart function in scleroderma: insights from myocardial Doppler tissue imaging","volume":"19","author":"Hsiao","year":"2006","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.hfc.2012.04.001_bib72","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1540-8175.2007.00365.x","article-title":"Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion","volume":"24","author":"Lee","year":"2007","journal-title":"Echocardiography"},{"key":"10.1016\/j.hfc.2012.04.001_bib73","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/art.23463","article-title":"Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: a controlled study of 100 consecutive patients","volume":"58","author":"Meune","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hfc.2012.04.001_bib74","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1183\/09031936.00135407","article-title":"Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension","volume":"31","author":"Overbeek","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hfc.2012.04.001_bib75","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","article-title":"Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension","volume":"27","author":"Williams","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2012.04.001_bib76","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1164\/rccm.200712-1876OC","article-title":"Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension","volume":"177","author":"Forfia","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib77","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/hrt.2005.069484","article-title":"Systemic sclerosis associated pulmonary hypertension: improved survival in the current era","volume":"92","author":"Williams","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.hfc.2012.04.001_bib78","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/rheumatology\/35.10.989","article-title":"Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients","volume":"35","author":"Koh","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib79","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in\u00a0primary pulmonary hypertension: the impact of\u00a0epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2012.04.001_bib80","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.hfc.2012.04.001_bib81","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0961203307087188","article-title":"An update in pulmonary hypertension in systemic lupus erythematosus\u2014do we need to know about it?","volume":"17","author":"Pope","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.hfc.2012.04.001_bib82","first-page":"985","volume":"188","author":"Haas","year":"2004","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib83","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00005792-198403000-00003","article-title":"A\u00a0prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease","volume":"63","author":"Sullivan","year":"1984","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.hfc.2012.04.001_bib84","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MD.0b013e3181579781","article-title":"Pulmonary arterial hypertension: a rare complication of primary Sj\u00f6gren syndrome: report of 9 new cases and review of the literature","volume":"86","author":"Launay","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.hfc.2012.04.001_bib85","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib86","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib87","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib88","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib89","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.hfc.2012.04.001_bib90","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2012.04.001_bib91","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJM199007053230106","article-title":"Regulatory functions of the vascular endothelium","volume":"323","author":"Vane","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib92","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A\u00a0comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib93","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension","volume":"338","author":"McLaughlin","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib94","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib95","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib96","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3899\/jrheum.081277","article-title":"Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol","volume":"36","author":"Badesch","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib97","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib98","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.hfc.2012.04.001_bib99","first-page":"1195","article-title":"Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma","volume":"26","author":"Farber","year":"1999","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1378\/chest.113.1.237","article-title":"Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease","volume":"113","author":"Palmer","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.hfc.2012.04.001_bib101","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/pcad.2002.130160","article-title":"Emerging medical therapies for pulmonary arterial hypertension","volume":"45","author":"Galie","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.hfc.2012.04.001_bib102","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2012.04.001_bib103","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib104","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions","volume":"65","author":"Denton","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.hfc.2012.04.001_bib105","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.healun.2004.12.113","article-title":"Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases","volume":"24","author":"Girgis","year":"2005","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.hfc.2012.04.001_bib106","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/ard.2007.080424","article-title":"Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension","volume":"67","author":"Iannone","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.hfc.2012.04.001_bib107","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1517\/14656566.7.11.1487","article-title":"Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial\u00a0hypertension, pulmonary fibrosis and digital\u00a0ulcers","volume":"7","author":"Jain","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.hfc.2012.04.001_bib108","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/ard.2007.069609","article-title":"Selective endothelin a receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease","volume":"66","author":"Girgis","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.hfc.2012.04.001_bib109","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2012.04.001_bib110","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib111","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.hfc.2012.04.001_bib112","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2012.04.001_bib113","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib114","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1183\/09031936.04.00051104","article-title":"Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension","volume":"24","author":"Hoeper","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hfc.2012.04.001_bib115","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib116","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1183\/09031936.00081706","article-title":"Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension","volume":"29","author":"Mathai","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hfc.2012.04.001_bib117","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2012.04.001_bib118","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1172\/JCI25399","article-title":"Lessons learned from cancer may help in the treatment of pulmonary hypertension","volume":"115","author":"Adnot","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hfc.2012.04.001_bib119","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hfc.2012.04.001_bib120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1152\/physiolgenomics.00169.2007","article-title":"Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension","volume":"33","author":"Moreno-Vinasco","year":"2008","journal-title":"Physiol Genomics"},{"issue":"9","key":"10.1016\/j.hfc.2012.04.001_bib121","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2012.04.001_bib122","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.trsl.2007.12.010","article-title":"Identification of candidate genes in scleroderma-related pulmonary arterial hypertension","volume":"151","author":"Grigoryev","year":"2008","journal-title":"Transl Res"},{"key":"10.1016\/j.hfc.2012.04.001_bib123","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00392-009-0752-3","article-title":"Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension","volume":"98","author":"ten Freyhaus","year":"2009","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.hfc.2012.04.001_bib124","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1002\/art.22264","article-title":"Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension","volume":"54","author":"Schachna","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.hfc.2012.04.001_bib125","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1183\/09031936.00139809","article-title":"Systemic sclerosis and bilateral lung transplantation: a single center experience","volume":"36","author":"Saggar","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hfc.2012.04.001_bib126","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.humpath.2006.11.022","article-title":"Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases","volume":"38","author":"Dorfmuller","year":"2007","journal-title":"Hum Pathol"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713612000256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713612000256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T11:56:12Z","timestamp":1542887772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713612000256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1551713612000256"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2012.04.001","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}